By: Els Dewulf
During the 27th annual BSMO meeting, Prof. Dr. Bertrand Tombal (Cliniques universitaires Saint-Luc) gave his view on future treatments and strategies within genitourinary (GU) malignancies, focusing on urothelial and prostate cancer. He noted that many of the drugs or combinations discussed may not be approved by EMA or reimbursed by RIZIV/INAMI.
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
